Effects of central nervous system drugs on driving: Speed variability versus standard deviation of lateral position as outcome measure of the on-The-Road driving test

Human Psychopharmacology

Volumn 29, Issue 1, 2014, Pages 19-24

  Verster, Joris C ^a,b   Roth, Thomas ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^c HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

driving; drugs; impairment; SD speed; SDLP; sensitivity

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; HYPNOTIC AGENT;

CAR DRIVING; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); CORRELATION ANALYSIS; DRIVING ABILITY; DRUG EFFECT; HUMAN; ON THE ROAD DRIVING TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; STANDARD DEVIATION OF LATERAL POSITION; STATISTICAL PARAMETERS; VELOCITY;

AUTOMOBILE DRIVING; CENTRAL NERVOUS SYSTEM AGENTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMOTOR PERFORMANCE;

EID: 84892599373     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2377     Document Type: Review

References (43)

1. Conen S, Theunissen EL, Van Oers AC, Valiente R, Ramaekers JG,. 2011. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 25: 1517-1523.
2. IMS Health. National Prescription Audit, Dec. 2010.
3. Leufkens TR, Vermeeren A,. 2009. Highway driving in the elderly the morning after bedtime use of hypnotics: a comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo. J Clin Psychopharmacol 29: 432-438.
4. Leufkens TR, Vermeeren A, Smink BE, van Ruitenbeek P, Ramaekers JG,. 2007. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. Psychopharmacology (Berl) 191: 951-959.
5. Leufkens TR, Lund JS, Vermeeren A,. 2009. Highway driving performance and cognitive functioning the morning after bedtime and middle-Of-The-Night use of gaboxadol, zopiclone and zolpidem. J Sleep Res 18: 387-396.
6. Louwerens JW, Gloerich ABM, De Vries G, Brookhuis KA, O'Hanlon JF,. 1987. The relationship between drivers' blood alcohol concentration (BAC) and actual driving performance during high travel speed. In Alcohol, Drugs and Traffic Safety, Noordzij PC, Roszbach R, (eds). Excerpta Medica: Amsterdam; 183-192.
7. Mets MAJ, de Vries JM, de Senerpont Domis LM, Volkerts ER, Olivier B, Verster JC,. 2011a. Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance and mood in healthy adult subjects. Sleep 34: 1327-1334.
8. Mets MAJ, Kuipers E, de Senerpont Domis LM, et al., 2011b. Effects of alcohol highway driving in the STISIM driving simulator. Hum Psychopharmacol 26: 434-439.
9. Mets MAJ, Alford C, Verster JC,. 2012. Sleep specialists' opinion on sleep disorders and fitness to drive: the necessity of continued education. Ind Health 50: 499-508.
10. O'Hanlon JF,. 1984. Driving under the influence of drugs: rationale for, and application of, a new test. Br J Clin Pharmacol 18 (Supplement 1): 121S-129S.
11. O'Hanlon JF, Haak TW, Blauw GJ, Riemersma JBJ,. 1982. Diazepam impairs lateral position control in highway driving. Science 217: 79-81.
12. O'Hanlon JF, Robbe HWJ, Vermeeren A, van Leeuwen C, Danjou PE,. 1998. Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing. J Clin Psychopharmacol 18: 212-221.
13. Owens K, Ramaekers JG,. 2009. Drugs, driving, and models to measure driving impairment. In Drugs, Driving and Traffic Safety, Verster JC, Pandi-Perumal SR, Ramaekers JG, de Gier JJ, (eds). Birkhauser Verlag AG: Basel, Switzerland.
14. Penning R, Veldstra J, Daamen AP, Olivier B, Verster JC,. 2010. Drugs of abuse, driving and traffic safety. Curr Drug Abuse Rev 3: 23-32.
15. Ramaekers JG,. 2003. Antidepressants and driver impairment: empirical evidence from a standard on-The-Road test. J Clin Psychiatry 64: 20-29.
16. Ramaekers JG, O'Hanlon JF,. 1994. Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. Eur J Clin Pharmacol 47: 261-266.
17. Ramaekers JG, Uiterwijk MM, O'Hanlon JF,. 1992. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 42: 363-369.
18. Riedel WJ, Schoenmakers EAJM, O'Hanlon JF,. 1989. Sedation and performance impairment with antihistamines. In Management of Allergy in the 1990s, Kaliner M, (ed.). Hans Huber Publishers: Toronto.
19. Riedel WJ, Ramaekers JG, Uiterwijk M, O'Hanlon JF,. 1990. Higher doses of terfenadine and loratadine. Acute and subchronic effects on psychomotor and actual driving performance. Technical Report 90-08, Institute for Drugs, Safety & Behavior. Maastricht, The Netherlands: University of Limburg, Instituut voor Geneesmiddelen, Veiligheid en Gedrag (IGVG).
20. Robbe HW, O'Hanlon JF,. 1990. Effects of acrivastine, acrivastine plus peudoephedrine, and triprolidine on highway driving. Technical report IGVG 90-12, Institute for Drugs, Safety and Behavior, University of Limburg.
21. Schoenmakers EA, Riedel WJ, de Gier JJ, van Dijke CPH, Beuman GH, O'Hanlon JF,. 1987. Het Effect van Terfenadine op de Rijvaardigheid van Geselecteerde Patiënten. Technical report, University of Limburg, Instituut voor Geneesmiddelen, Veiligheid en Gedrag, Maastricht, The Netherlands. ISBN 90-5147-001-0.
22. Schoenmakers EAJM, Robbe HWJ, O'Hanlon JF,. 1989. Acute and subchronic effects of the antidepressants levoprotiline and doxepin on the performance of healthy volunteers in psychometric and actual driving tests. Technical Report, University of Maastricht, Institute for Human Psychopharmacology, Maastricht, The Netherlands.
23. Theunissen EL, Vermeeren A, van Oers AC, van Maris I, Ramaekers JG,. 2004. A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo. Clin Exp Allergy 34: 250-258.
24. Van Laar MW, Volkerts ER, Van Willigenburg APP,. 1992. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 12: 86-95.
25. Van Laar MW, van Willigenburg AP, Volkerts ER,. 1995. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 15: 30-40.
26. Van Laar MW, Volkerts ER, Verbaten MN,. 2001. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2a/2c antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psychopharmacology (Berl) 154: 189-197.
27. Vermeeren A, Ramaekers JG, van Leeuwen CJ, O'Hanlon JF,. 1998a. Residual effects on actual car driving of evening dosing of chlorpheniramine 8 and 12 mg when used with terfenadine 60 mg in the morning. Hum Psychopharmacol 13: S79-S86.
28. Vermeeren A, Danjou PE, O'Hanlon JF,. 1998b. Residual effects of evening and middle-Of-The-Night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol 13: S98-S107.
29. Vermeeren A, Riedel WJ, van Boxtel MP, Darwish M, Paty I, Patat A,. 2002. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 25: 224-231.
30. Verster JC, Mets MAJ,. 2009. Psychoactive medication and traffic safety. Int J Environ Res Public Health 6: 1041-1054.
31. Verster JC, Roth T,. 2011. Standard operation procedures for conducting the on-The-Road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J Gen Med 4: 359-371.
32. Verster JC, Roth T,. 2012. Predicting psychopharmacological drug effects on actual driving (SDLP) from psychometric tests measuring driving-related skills. Psychopharmacology (Berl) 220: 293-301.
33. Verster JC, Volkerts ER, Verbaten MN,. 2002a. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study. Neuropsychopharmacology 27: 260-269.
34. Verster JC, Volkerts ER, Schreuder AHCML, et al., 2002b. Residual effects of middle-Of-The-Night administration of zaleplon and zolpidem on driving ability, memory functions and psychomotor performance. J Clin Psychopharmacol 22: 576-583.
35. Verster JC, de Weert AM, Bijtjes SI, et al., 2003. Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo controlled trial. Psychopharmacology (Berl) 169: 84-90.
36. Verster JC, Pandi-Perumal SR, Ramaekers JHG, De Gier JJ, (eds). Drugs, Driving and Traffic Safety. Birkhauser Verlag: Basel, Switzerland, 2009.
37. Volkerts ER, de Vries G, Meijer T, O'Hanlon JF,. 1984a. Driving performance the day after use of loprazolam, flunitrazepam and placebo. Technical Report VK 83-04, Traffic Research Centre, University of Groningen, The Netherlands.
38. Volkerts ER, Louwerens JW, Gloerich ABM, Brookhuis KA, O'Hanlon JF,. 1984b. Zopiclone's residual effect upon actual driving performance versus those of nitrazepam and flunitrazepam. Technical Report VK 84-10, Traffic Research Centre, Groningen, The Netherlands.
39. Volkerts ER, Brookhuis KA, O'Hanlon JF,. 1987. Comparison of the effects of buspirone 5 mg and 10 mg, diazepam 5 mg and lorazepam 1 mg (t.i.d.) upon actual driving performance. Technical Report VK 87-02, Traffic Research Centre, University of Groningen, The Netherlands.
40. Volkerts ER, van Willigenburg AP, van Laar MW, Maes RA,. 1992a. Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric test performance and daytime sleepiness. Hum Psychopharmacol 7: 227-238.
41. Volkerts ER, van Laar MW, van Willigenburg APP, Maes RAA,. 1992b. A comparative study of on-The-Road and simulated driving performance after nocturnal treatment with lormetazepam 1 mg and oxazepam 50 mg. Hum Psychopharmacol 7: 297-309.
42. Vuurman E, Theunissen E, van Oers A, van Leeuwen C, Jolles J,. 2007. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum Psychopharmacol 22: 289-297.
43. Wingen M, Bothmer J, Langer S, Ramaekers JG,. 2005. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 66: 436-443.